Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ZN-A-1041 |
Synonyms | |
Therapy Description |
ZN-A-1041 inhibits ERBB2 (HER2)-mediated downstream signaling, potentially resulting in tumor cell death (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZN-A-1041 | ZN-A 1041|ZN-A1041 | HER2 Inhibitor 42 | ZN-A-1041 inhibits ERBB2 (HER2)-mediated downstream signaling, potentially resulting in tumor cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05593094 | Phase I | ZN-A-1041 Ado-trastuzumab emtansine + ZN-A-1041 Trastuzumab deruxtecan + ZN-A-1041 Pertuzumab/trastuzumab/hyaluronidase-zzxf + ZN-A-1041 Pertuzumab + Trastuzumab + ZN-A-1041 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors | Recruiting | USA | NZL | GBR | FRA | ESP | AUS | 0 |